This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dr. Lillian Sung In this Friday’s PCT Grand Rounds, Lillian Sung of the Hospital for Sick Children will present “Improving Symptom Control in Pediatric Cancer Patients With SSPedi and SPARK.” The Grand Rounds session will be held on Friday, February 7, 2025, at 1:00 pm eastern. The Symptom Screening in Pediatrics Tool (SSPedi) is a validated approach to measuring bothersome symptoms in pediatric patients receiving cancer treatments.
Celltrions Actemra (tocilizumab) biosimilar Avtozma (tocilizumab-anoh) has received FDA approval for multiple indications, including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) as well as COVID-19. The approval encompasses both intravenous (IV) and subcutaneous (SC) formulations, offering flexibility in administration.
The Latin American Pharmaceutical Market: Why Specialty Generics Are Poised for Growth As the pharmaceutical industry continues to evolve, one trend is becoming increasingly clear: the demand for specialty generics is on the rise, particularly in the Latin American market. But what exactly are specialty generics, and why are they gaining traction in this region?
(courtneyk/Getty Images) Research on the gut microbiome has triggered a ‘revolution‘ in nutritional science, and in the last few years, dietary fiber has become the “new protein” added to foods in abundance to feed our gut and boost our health. A recent study on mice, however, suggests not all fiber supplements are equally beneficial.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
As many as 20% to 50% of clinical trials do not accrue participants at the site level, leading to wasted time and financial resources. This waste can be minimized by early selection of trials most likely to succeed. The protocol feasibility review process informs this selection by offering a way to evaluate logistical elements of a clinical trial before the activation process is started.
Metsera, Inc., a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 per share, raising $275 million in gross proceeds. Current Share Price: The offering, which includes 15,277,778 shares of common stock, is set to close on February 3, 2025, after beginning trading on the Nasdaq under the ticker sy
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
In an increasingly competitive market, organizations involved in clinical trials or participant-driven research programs cannot afford to have a cumbersome or confusing recruitment and enrollment process. A seamless, efficient, and supportive experiencefrom first contact to trial participationcan make all the difference in attracting and retaining participants, ultimately ensuring the success of your trial.
In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics , a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Dr. Marcondes is a licensed and trained physician, specializing in oncology and immune oncology. He has more than 15 years of research and teaching experience in Bone Marrow Transplant (BMT)/Cellular Therapies and more than 10 years of industry experience.
Integrating E-Clinical Technologies in smarter clinical trials improves efficiency, enhances data accuracy, and streamlines clinical research for better patient outcomes. With the increasing world population, clinical trials are now more […] The post The Role of Integrating E-Clinical Technologies In Smarter Clinical Trials appeared first on ProRelix Research.
During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a detailed review of its achievements in 2024 and outlining its 2025 plans.
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, shares how the imposed/pending trade tariffs impact pharma manufacturers.
Emerging animal diseases Event type: symposium Audience: scientists Description: Sciensano organises together with the Federal Agency for the Safety of the Food Chain ( FASFC ), ARSIA and DGZ , the 10th symposium on animal health. The spoken language of this event is Dutch or French. Hence, more information about this course can be found on the Dutch or French version of the event page.
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
144 
Let's personalize your content